479 related articles for article (PubMed ID: 33804869)
21. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
Joshi M; Ansell SM
J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
[TBL] [Abstract][Full Text] [Related]
22. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
23. The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.
Chang RB; Beatty GL
J Leukoc Biol; 2020 Jul; 108(1):363-376. PubMed ID: 32272502
[TBL] [Abstract][Full Text] [Related]
24. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint blockade in lymphoma.
Armand P
Hematology Am Soc Hematol Educ Program; 2015; 2015():69-73. PubMed ID: 26637703
[TBL] [Abstract][Full Text] [Related]
26. [The immune microenvironment in malignant lymphoma].
Nishikori M
Rinsho Ketsueki; 2019; 60(9):1229-1235. PubMed ID: 31597848
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
Li F; Chen Y; Pang M; Yang P; Jing H
Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
[TBL] [Abstract][Full Text] [Related]
28. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
30. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
31. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
32. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
33. Tumor Microenvironment in T-Cell Lymphomas.
Bennani NN; Ansell SM
Cancer Treat Res; 2019; 176():69-82. PubMed ID: 30596213
[TBL] [Abstract][Full Text] [Related]
34. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
35. Effects of Radiation on the Tumor Microenvironment.
Monjazeb AM; Schalper KA; Villarroel-Espindola F; Nguyen A; Shiao SL; Young K
Semin Radiat Oncol; 2020 Apr; 30(2):145-157. PubMed ID: 32381294
[TBL] [Abstract][Full Text] [Related]
36. Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment.
Watanabe T
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008305
[TBL] [Abstract][Full Text] [Related]
37. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
[TBL] [Abstract][Full Text] [Related]
38. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
39. The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma.
Ansell SM
Cancer Immunol Res; 2019 May; 7(5):696-700. PubMed ID: 31043393
[TBL] [Abstract][Full Text] [Related]
40. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
